David Telander News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from David Telander. Real-time updates on events, politics, business and more.

OpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit

May 6, 2024

BCVA gains of +5.5 letters at 24 months in Cohort 4 patients BCVA gains of +7.4 letters among Cohort 4 patients with extensive OpRegen bleb coverage of the GA lesion Maintenance or increases...

Israel General United States David Telander Brianm Culley Roche Group Foundation Fighting Blindness

Source: marketscreener.com

RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit

March 13, 2024

Lineage Cell Therapeutics, Inc. , a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that 24 month results from patients enrolled in...

United States David Telander Lineage Cell Therapeutics Inc Casey Eye Institute Retinal Consultants Medical Group Exchange Commission

Source: marketscreener.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science

Navigation

David Telander News Today

OpRegen&#xAE; (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit

RG6501 (OpRegen&#xAE;) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit

Explore More Categories

OpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit

RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit